G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN 4.8% Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genomed SA
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Total Equity
zł10.1m
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Total Equity
zł129.3m
CAGR 3-Years
100%
CAGR 5-Years
N/A
CAGR 10-Years
5%
R
Read Gene SA
WSE:RDG
Total Equity
zł1.5m
CAGR 3-Years
-29%
CAGR 5-Years
-11%
CAGR 10-Years
-7%
B
Bioton SA
WSE:BIO
Total Equity
zł595.2m
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-8%
U
Urteste SA
WSE:URT
Total Equity
zł27.7m
CAGR 3-Years
245%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Total Equity
zł113.6m
CAGR 3-Years
24%
CAGR 5-Years
30%
CAGR 10-Years
7%
No Stocks Found

Genomed SA
Glance View

Market Cap
34.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Overvaluation 3%
Intrinsic Value
Price
G

See Also

What is Genomed SA's Total Equity?
Total Equity
10.1m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Total Equity amounts to 10.1m PLN.

What is Genomed SA's Total Equity growth rate?
Total Equity CAGR 5Y
6%

Over the last year, the Total Equity growth was 10%. The average annual Total Equity growth rates for Genomed SA have been 10% over the past three years , 6% over the past five years .

Back to Top